In the present study, using 3D skin models, dry skin and AD model mice, we found that the topical application of the SPCM (+) cream to the skin with weakened barrier function suppressed inflammation (increased levels of IL‐36γ and TSLP), disruption of skin barrier function (increase in TEWL), and itching (increased number of scratching bouts), by preventing the entry of foreign proteases and living mites into the body. Here, TSLP is linked to Alzheimer disease.